Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

TuberculosisMeningitis

Interventions

DRUG

Contezolid

Contezolid 800mg once daily (QD) for 7 days;

DRUG

Linezolid (LZD)

Linezolid 600mg once daily (QD) for 7 days.

Trial Locations (1)

Beijing chest hospital affiliated to Capital medical university, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing

All Listed Sponsors

lead

Beijing Chest Hospital

OTHER